Product image of Levodopa + Carbidopa + Entacapona Generis (Carbidopa, Entacapone, Levodopa) supplied by GNH India

Levodopa + Carbidopa + Entacapona Generis

Active Ingredient:
Carbidopa, Entacapone, Levodopa
Origin:
EU

Levodopa + Carbidopa + Entacapona Generis (Carbidopa, Entacapone, Levodopa)

Levodopa, Carbidopa, Entacapone, the active ingredients in Levodopa + Carbidopa + Entacapone Generis, are a dopamine precursor combined with a peripheral decarboxylase inhibitor and a catechol‑O‑methyltransferase inhibitor, presented as an oral tablet for systemic use. The combination is used to treat Parkinson's disease and to manage motor fluctuations in patients already receiving levodopa therapy.

GNH India supplies Levodopa + Carbidopa + Entacapone Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Generis Farmacêutica, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Levodopa/Carbidopa/Entacapone is indicated for the treatment of Parkinsonian disorders and related motor complications.

  • Parkinson's disease: Improves bradykinesia, rigidity, tremor and overall motor function.
  • Motor fluctuations in Parkinson's disease: Reduces "off" periods and extends "on" time when added to levodopa therapy.
  • Adjunct therapy for levodopa‑responsive Parkinsonism: Enhances central dopamine availability and stabilises symptom control.

How It Works

  • Levodopa is absorbed and crosses the blood‑brain barrier, where it is decarboxylated to dopamine. Carbidopa inhibits peripheral aromatic L‑amino‑acid decarboxylase, preventing premature conversion of levodopa and increasing its central concentration. Entacapone blocks catechol‑O‑methyltransferase (COMT) in the periphery, reducing levodopa metabolism and extending its plasma half‑life, thereby providing more stable dopaminergic stimulation.

Side Effects

Levodopa/Carbidopa/Entacapone may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Vomiting: occasional episodes, especially at treatment initiation.
  • Orthostatic hypotension: dizziness upon standing.
  • Dyskinesia: involuntary movements, often dose‑related.
  • Hallucinations: visual disturbances, more common in older patients.
  • Insomnia: difficulty maintaining sleep.

Serious or Rare Side Effects

  • Neuroleptic malignant syndrome: life‑threatening reaction with fever and rigidity.
  • Severe depression or suicidal thoughts: requires immediate medical attention.
  • Pulmonary edema: rare fluid accumulation in lungs.
  • Severe arrhythmias: uncommon cardiac rhythm disturbances.

Precautions & Warnings

When prescribing Levodopa/Carbidopa/Entacapone, clinicians should consider several precautionary measures to ensure safe use.

  • Assess cardiovascular status: monitor blood pressure for orthostatic changes.
  • Evaluate psychiatric history: watch for hallucinations or mood alterations.
  • Adjust dose in renal impairment: consider reduced dosing in severe dysfunction.
  • Review concomitant medications: avoid drugs that may exacerbate dyskinesia.
  • Monitor for dyskinesia development: titrate levodopa component as needed.
  • Store at ambient temperature: keep below 25 °C in the original container, protect from moisture.

Avoid Interactions

Levodopa/Carbidopa/Entacapone interacts with several medicines that can alter its efficacy or safety profile.

Major Interactions (Avoid)

  • Non‑selective MAO inhibitors: risk of hypertensive crisis.
  • Antipsychotics (e.g., haloperidol): may diminish dopaminergic effect.
  • High‑dose pyridoxine (vitamin B6): accelerates peripheral levodopa metabolism.

Moderate Interactions (Monitor Closely)

  • Antihypertensives: additive blood‑pressure lowering effect.
  • Iron or calcium supplements: reduce levodopa absorption if taken simultaneously.
  • SSRIs or SNRIs: may increase risk of serotonin syndrome when combined with MAO‑B inhibitors.

Frequently Asked Questions

Levodopa + Carbidopa + Entacapone is prescribed to treat Parkinson's disease and to manage motor fluctuations in patients who experience "off" periods while on levodopa therapy. It helps improve overall motor function and reduces the variability of symptom control.

Levodopa crosses the blood‑brain barrier and is converted to dopamine. Carbidopa blocks peripheral decarboxylation, increasing the amount of levodopa that reaches the brain. Entacapone inhibits the COMT enzyme, slowing peripheral metabolism of levodopa and extending its plasma half‑life, resulting in more consistent dopaminergic stimulation.

The appropriate dose of Levodopa + Carbidopa + Entacapone is determined individually by a qualified prescriber based on the patient’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made according to therapeutic goals and side‑effect profile.

The safety of Levodopa + Carbidopa + Entacapone in pregnancy or while breastfeeding has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the prescribing clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with levodopa alone, the addition of carbidopa reduces peripheral side effects and increases central availability, while entacapone further prolongs levodopa’s half‑life by inhibiting COMT. This triple combination often provides smoother motor control than levodopa monotherapy and can be more convenient than using separate COMT‑inhibitor tablets.

Levodopa + Carbidopa + Entacapone tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children.

The product is taken orally, usually with a glass of water. It may be administered with or without food, but consistent timing relative to meals can help minimise gastrointestinal side effects. Patients should follow the prescriber’s instructions regarding timing and any dose‑splitting.

Serious risks include neuroleptic malignant syndrome, severe depression or suicidal ideation, pulmonary edema, and rare cardiac arrhythmias. Any sudden change in mood, fever, muscle rigidity, or difficulty breathing should prompt immediate medical evaluation.

Patients with known hypersensitivity to levodopa, carbidopa, entacapone, or any excipients should avoid this medication. It is also contraindicated in individuals taking non‑selective MAO inhibitors. Caution is advised in patients with severe cardiovascular disease, uncontrolled hypertension, or a history of psychiatric disorders.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Carbidopa, Entacapone, Levodopa

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT